Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (121-130 of 280) with videos related to

Pageof 28
Sort By:
Metabolism: Clinical and Experimental|August 11, 2019
The metabolic regulator small heterodimer partner contributes to the glucose and lipid homeostasis abnormalities induced by hepatitis C virus infectionJizheng Chen, Yue Zhou, Yuan Zhuang, et al.
Cellular & Molecular Immunology|December 23, 2014
Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patientsNaicui Zhai, Xiumei Chi, Tianyang Li, et al.
Plos One|January 24, 2017
Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 SignalingNaicui Zhai, Haijun Li, Hongxiao Song, et al.
Clinical Therapeutics|September 7, 2018
Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjectsXiaojiao Li, Hong Chen, Junqi Niu, et al.
Frontiers in Pharmacology|November 2, 2020
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy SubjectsHong Zhang, Min Wu, Xiaoxue Zhu, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2020
Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infectionHong Zhang, Yue Hu, Min Wu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 6, 2021
A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjectsCuiyun Li, Wei Xiang, Min Wu, et al.
Mbio|May 19, 2022
Dual-Role of Cholesterol-25-Hydroxylase in Regulating Hepatitis B Virus Infection and ReplicationQi Wei, Hongxiao Song, Yanli Gao, et al.
Expert Opinion on Investigational Drugs|January 6, 2021
Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individualsYue Hu, Hong Zhang, Min Wu, et al.
Experimental and Therapeutic Medicine|April 29, 2017
Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis BXu Li, Qinglong Jin, Hong Zhang, et al.
Pageof 28

Showing results (121-130 of 280) with videos related to

Sort By:
Pageof 28
Metabolism: Clinical and Experimental|August 11, 2019
The metabolic regulator small heterodimer partner contributes to the glucose and lipid homeostasis abnormalities induced by hepatitis C virus infectionJizheng Chen, Yue Zhou, Yuan Zhuang, et al.
Cellular & Molecular Immunology|December 23, 2014
Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patientsNaicui Zhai, Xiumei Chi, Tianyang Li, et al.
Plos One|January 24, 2017
Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 SignalingNaicui Zhai, Haijun Li, Hongxiao Song, et al.
Clinical Therapeutics|September 7, 2018
Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjectsXiaojiao Li, Hong Chen, Junqi Niu, et al.
Frontiers in Pharmacology|November 2, 2020
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy SubjectsHong Zhang, Min Wu, Xiaoxue Zhu, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2020
Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infectionHong Zhang, Yue Hu, Min Wu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 6, 2021
A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjectsCuiyun Li, Wei Xiang, Min Wu, et al.
Mbio|May 19, 2022
Dual-Role of Cholesterol-25-Hydroxylase in Regulating Hepatitis B Virus Infection and ReplicationQi Wei, Hongxiao Song, Yanli Gao, et al.
Expert Opinion on Investigational Drugs|January 6, 2021
Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individualsYue Hu, Hong Zhang, Min Wu, et al.
Experimental and Therapeutic Medicine|April 29, 2017
Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis BXu Li, Qinglong Jin, Hong Zhang, et al.
Pageof 28